Pfizer, Abbott Ink Deal to Develop Companion Dx for PGx-based NSCLC Drug | GenomeWeb

By Turna Ray

Abbott Molecular Diagnostics announced last week it is developing a genetic test that will determine which non-small cell lung cancer patients should receive Pfizer's investigational drug known as PF-02341066. The deal is the second announced by Abbott in the last two months to develop a pharmacogenomic-based companion diagnostic for a NSCLC drug with a major drugmaker.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.